Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119


Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.

Clark CG, Rossi KA, Corte JR, Fang T, Smallheer JM, De Lucca I, Nirschl DS, Orwat MJ, Pinto DJP, Hu Z, Wang Y, Yang W, Jeon Y, Ewing WR, Myers JE Jr, Sheriff S, Lou Z, Bozarth JM, Wu Y, Rendina A, Harper T, Zheng J, Xin B, Xiang Q, Luettgen JM, Seiffert DA, Wexler RR, Lam PYS.

Bioorg Med Chem Lett. 2019 Oct 1;29(19):126604. doi: 10.1016/j.bmcl.2019.08.008. Epub 2019 Aug 16.


Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.

Miller MM, Banville J, Friends TJ, Gagnon M, Hangeland JJ, Lavallée JF, Martel A, O'Grady H, Rémillard R, Ruediger E, Tremblay F, Posy SL, Allegretto NJ, Guarino VR, Harden DG, Harper TW, Hartl K, Josephs J, Malmstrom S, Watson C, Yang Y, Zhang G, Wong P, Yang J, Bouvier M, Seiffert DA, Wexler RR, Lawrence RM, Priestley ES, Marinier A.

J Med Chem. 2019 Aug 22;62(16):7400-7416. doi: 10.1021/acs.jmedchem.9b00186. Epub 2019 Aug 5.


Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.

Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV.

Eur J Heart Fail. 2019 Aug;21(8):1022-1031. doi: 10.1002/ejhf.1504. Epub 2019 Jun 6.


Beyond medical actionability: Public perceptions of important actions in response to hypothetical genetic testing results.

Seiffert DJ, McCarthy Veach P, LeRoy B, Guan W, Zierhut H.

J Genet Couns. 2019 Apr;28(2):355-366. doi: 10.1002/jgc4.1048. Epub 2019 Feb 2.


Factor XIa Inhibitors as New Anticoagulants.

Quan ML, Pinto DJP, Smallheer JM, Ewing WR, Rossi KA, Luettgen JM, Seiffert DA, Wexler RR.

J Med Chem. 2018 Sep 13;61(17):7425-7447. doi: 10.1021/acs.jmedchem.8b00173. Epub 2018 May 18. Review.


Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.

Hu Z, Wang C, Han W, Rossi KA, Bozarth JM, Wu Y, Sheriff S, Myers JE Jr, Luettgen JM, Seiffert DA, Wexler RR, Quan ML.

Bioorg Med Chem Lett. 2018 Apr 1;28(6):987-992. doi: 10.1016/j.bmcl.2018.02.049. Epub 2018 Feb 27.


First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.

Perera V, Luettgen JM, Wang Z, Frost CE, Yones C, Russo C, Lee J, Zhao Y, LaCreta FP, Ma X, Knabb RM, Seiffert D, DeSouza M, Mugnier P, Cirincione B, Ueno T, Frost RJA.

Br J Clin Pharmacol. 2018 May;84(5):876-887. doi: 10.1111/bcp.13520. Epub 2018 Mar 5.


Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).

Pinto DJP, Orwat MJ, Smith LM 2nd, Quan ML, Lam PYS, Rossi KA, Apedo A, Bozarth JM, Wu Y, Zheng JJ, Xin B, Toussaint N, Stetsko P, Gudmundsson O, Maxwell B, Crain EJ, Wong PC, Lou Z, Harper TW, Chacko SA, Myers JE Jr, Sheriff S, Zhang H, Hou X, Mathur A, Seiffert DA, Wexler RR, Luettgen JM, Ewing WR.

J Med Chem. 2017 Dec 14;60(23):9703-9723. doi: 10.1021/acs.jmedchem.7b01171. Epub 2017 Nov 17.


Macrocyclic factor XIa inhibitors.

Wang C, Corte JR, Rossi KA, Bozarth JM, Wu Y, Sheriff S, Myers JE Jr, Luettgen JM, Seiffert DA, Wexler RR, Quan ML.

Bioorg Med Chem Lett. 2017 Sep 1;27(17):4056-4060. doi: 10.1016/j.bmcl.2017.07.048. Epub 2017 Jul 25.


Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.

Corte JR, Yang W, Fang T, Wang Y, Osuna H, Lai A, Ewing WR, Rossi KA, Myers JE Jr, Sheriff S, Lou Z, Zheng JJ, Harper TW, Bozarth JM, Wu Y, Luettgen JM, Seiffert DA, Quan ML, Wexler RR, Lam PYS.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3833-3839. doi: 10.1016/j.bmcl.2017.06.058. Epub 2017 Jun 23.


Neutral macrocyclic factor VIIa inhibitors.

Wurtz NR, Parkhurst BL, DeLucca I, Glunz PW, Jiang W, Zhang X, Cheney DL, Bozarth JM, Rendina AR, Wei A, Harper T, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.

Bioorg Med Chem Lett. 2017 Jun 15;27(12):2650-2654. doi: 10.1016/j.bmcl.2017.04.008. Epub 2017 Apr 19.


Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors.

Richter JM, Cheney DL, Bates JA, Wei A, Luettgen JM, Rendina AR, Harper TM, Narayanan R, Wong PC, Seiffert D, Wexler RR, Priestley ES.

ACS Med Chem Lett. 2016 Nov 1;8(1):67-72. doi: 10.1021/acsmedchemlett.6b00375. eCollection 2017 Jan 12.


Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.

Corte JR, Fang T, Osuna H, Pinto DJ, Rossi KA, Myers JE Jr, Sheriff S, Lou Z, Zheng JJ, Harper TW, Bozarth JM, Wu Y, Luettgen JM, Seiffert DA, Decicco CP, Wexler RR, Quan ML.

J Med Chem. 2017 Feb 9;60(3):1060-1075. doi: 10.1021/acs.jmedchem.6b01460. Epub 2017 Jan 31.


Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.

Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, Callejo M, Miller MM, Lawrence RM, Banville J, Guy J, Maxwell BD, Priestley ES, Marinier A, Wexler RR, Bouvier M, Gordon DA, Schumacher WA, Yang J.

Sci Transl Med. 2017 Jan 4;9(371). pii: eaaf5294. doi: 10.1126/scitranslmed.aaf5294.


Inhibition of Factor XIa Reduces the Frequency of Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.

Wang X, Kurowski S, Wu W, Castriota GA, Zhou X, Chu L, Ellsworth KP, Chu D, Edmondson S, Ali A, Andre P, Seiffert D, Erion M, Gutstein DE, Chen Z.

J Pharmacol Exp Ther. 2017 Mar;360(3):476-483. doi: 10.1124/jpet.116.238600. Epub 2016 Dec 29.


Factor XIIa as a Novel Target for Thrombosis: Target Engagement Requirement and Efficacy in a Rabbit Model of Microembolic Signals.

Barbieri CM, Wang X, Wu W, Zhou X, Ogawa AM, O'Neill K, Chu D, Castriota G, Seiffert DA, Gutstein DE, Chen Z.

J Pharmacol Exp Ther. 2017 Mar;360(3):466-475. doi: 10.1124/jpet.116.238493. Epub 2016 Dec 29.


Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.

Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.

ACS Med Chem Lett. 2016 Sep 17;7(12):1077-1081. eCollection 2016 Dec 8.


Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.

Ladziata VU, Glunz PW, Zou Y, Zhang X, Jiang W, Jacutin-Porte S, Cheney DL, Wei A, Luettgen JM, Harper TM, Wong PC, Seiffert D, Wexler RR, Priestley ES.

Bioorg Med Chem Lett. 2016 Oct 15;26(20):5051-5057. doi: 10.1016/j.bmcl.2016.08.088. Epub 2016 Aug 28.


Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.

Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.

J Med Chem. 2016 Aug 11;59(15):7125-37. doi: 10.1021/acs.jmedchem.6b00469. Epub 2016 Aug 2.


Apixaban Inhibits Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.

Zhou X, Wu W, Chu L, Gutstein DE, Seiffert D, Wang X.

J Pharmacol Exp Ther. 2016 Sep;358(3):405-12. doi: 10.1124/jpet.116.234575. Epub 2016 Jul 6.


A rabbit model of cerebral microembolic signals for translational research: preclinical validation for aspirin and clopidogrel.

Zhou X, Kurowski S, Wu W, Desai K, Chu L, Gutstein DE, Seiffert D, Wang X.

J Thromb Haemost. 2016 Sep;14(9):1855-66. doi: 10.1111/jth.13377. Epub 2016 Jul 20.


Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.

Corte JR, Fang T, Pinto DJ, Orwat MJ, Rendina AR, Luettgen JM, Rossi KA, Wei A, Ramamurthy V, Myers JE Jr, Sheriff S, Narayanan R, Harper TW, Zheng JJ, Li YX, Seiffert DA, Wexler RR, Quan ML.

Bioorg Med Chem. 2016 May 15;24(10):2257-72. doi: 10.1016/j.bmc.2016.03.062. Epub 2016 Apr 1.


Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target.

Ankrom W, Wood HB, Xu J, Geissler W, Bateman T, Chatterjee MS, Feng KI, Metzger JM, Strapps WR, Tadin-Strapps M, Seiffert D, Andre P.

Pharmacol Res Perspect. 2016 Jan 15;4(1):e00207. doi: 10.1002/prp2.207. eCollection 2016 Feb.


Novel phenylalanine derived diamides as Factor XIa inhibitors.

Smith LM 2nd, Orwat MJ, Hu Z, Han W, Wang C, Rossi KA, Gilligan PJ, Pabbisetty KB, Osuna H, Corte JR, Rendina AR, Luettgen JM, Wong PC, Narayanan R, Harper TW, Bozarth JM, Crain EJ, Wei A, Ramamurthy V, Morin PE, Xin B, Zheng J, Seiffert DA, Quan ML, Lam PYS, Wexler RR, Pinto DJP.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):472-478. doi: 10.1016/j.bmcl.2015.11.089. Epub 2015 Nov 26.


Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.

Bhal V, Herr MJ, Dixon M, Akins S, Hord E, White MM, Seiffert D, Kotha J, Jennings LK.

Thromb Res. 2015 Dec;136(6):1216-23. doi: 10.1016/j.thromres.2015.09.009. Epub 2015 Sep 11.


In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa.

Wong PC, Quan ML, Watson CA, Crain EJ, Harpel MR, Rendina AR, Luettgen JM, Wexler RR, Schumacher WA, Seiffert DA.

J Thromb Thrombolysis. 2015 Nov;40(4):416-23. doi: 10.1007/s11239-015-1258-7.


Factor XII full and partial null in rat confers robust antithrombotic efficacy with no bleeding.

Cai TQ, Wu W, Shin MK, Xu Y, Jochnowitz N, Zhou Y, Hoos L, Bentley R, Strapps W, Thankappan A, Metzger JM, Ogletree ML, Tadin-Strapps M, Seiffert DA, Chen Z.

Blood Coagul Fibrinolysis. 2015 Dec;26(8):893-902. doi: 10.1097/MBC.0000000000000337.


In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.

Hawes BE, Zhai Y, Hesk D, Wirth M, Wei H, Chintala M, Seiffert D.

Eur J Pharmacol. 2015 Sep 5;762:221-8. doi: 10.1016/j.ejphar.2015.05.046. Epub 2015 May 27.


Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Hu Z, Wong PC, Gilligan PJ, Han W, Pabbisetty KB, Bozarth JM, Crain EJ, Harper T, Luettgen JM, Myers JE Jr, Ramamurthy V, Rossi KA, Sheriff S, Watson CA, Wei A, Zheng JJ, Seiffert DA, Wexler RR, Quan ML.

ACS Med Chem Lett. 2015 Apr 8;6(5):590-5. doi: 10.1021/acsmedchemlett.5b00066. eCollection 2015 May 14.


Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.

Cai TQ, Wickham LA, Sitko G, Michener MS, Raubertas R, Handt L, Chintala M, Seiffert D, Forrest M.

Eur J Pharmacol. 2015 Jul 5;758:107-14. doi: 10.1016/j.ejphar.2015.03.073. Epub 2015 Apr 7.


Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability.

Metzger JM, Tadin-Strapps M, Thankappan A, Strapps WR, DiPietro M, Leander K, Zhang Z, Shin MK, Levorse J, Desai K, Xu Y, Lai K, Wu W, Chen Z, Cai TQ, Jochnowitz N, Bentley R, Hoos L, Zhou Y, Sepp-Lorenzino L, Seiffert D, Andre P.

Thromb Haemost. 2015 Jun;113(6):1300-11. doi: 10.1160/TH14-06-0505. Epub 2015 Mar 19.


Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening.

Cheney DL, Bozarth JM, Metzler WJ, Morin PE, Mueller L, Newitt JA, Nirschl AH, Rendina AR, Tamura JK, Wei A, Wen X, Wurtz NR, Seiffert DA, Wexler RR, Priestley ES.

J Med Chem. 2015 Mar 26;58(6):2799-808. doi: 10.1021/jm501982k. Epub 2015 Mar 12.


Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.

Pinto DJ, Smallheer JM, Corte JR, Austin EJ, Wang C, Fang T, Smith LM 2nd, Rossi KA, Rendina AR, Bozarth JM, Zhang G, Wei A, Ramamurthy V, Sheriff S, Myers JE Jr, Morin PE, Luettgen JM, Seiffert DA, Quan ML, Wexler RR.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1635-42. doi: 10.1016/j.bmcl.2015.01.028. Epub 2015 Feb 4.


Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit.

Chen Z, Luo B, Cai TQ, Thankappan A, Xu Y, Wu W, DiMuzio J, Lifsted T, DiPietro M, Disa J, Ng B, Leander K, Clark S, Hoos L, Zhou Y, Jochnowitz N, Jachec C, Szczerba P, Gindy ME, Strapps W, Sepp-Lorenzino L, Seiffert DA, Lubbers L, Tadin-Strapps M.

Mol Ther Nucleic Acids. 2015 Jan 27;4:e224. doi: 10.1038/mtna.2014.75.


Pyridine and pyridinone-based factor XIa inhibitors.

Corte JR, Fang T, Hangeland JJ, Friends TJ, Rendina AR, Luettgen JM, Bozarth JM, Barbera FA, Rossi KA, Wei A, Ramamurthy V, Morin PE, Seiffert DA, Wexler RR, Quan ML.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):925-30. doi: 10.1016/j.bmcl.2014.12.050. Epub 2014 Dec 31.


Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.

Hangeland JJ, Friends TJ, Rossi KA, Smallheer JM, Wang C, Sun Z, Corte JR, Fang T, Wong PC, Rendina AR, Barbera FA, Bozarth JM, Luettgen JM, Watson CA, Zhang G, Wei A, Ramamurthy V, Morin PE, Bisacchi GS, Subramaniam S, Arunachalam P, Mathur A, Seiffert DA, Wexler RR, Quan ML.

J Med Chem. 2014 Dec 11;57(23):9915-32. doi: 10.1021/jm5010607. Epub 2014 Dec 2.


4-Benzothiazole-7-hydroxyindolinyl diaryl ureas are potent P2Y1 antagonists with favorable pharmacokinetics: low clearance and small volume of distribution.

Qiao JX, Wang TC, Hiebert S, Hu CH, Schumacher WA, Spronk SA, Clark CG, Han Y, Hua J, Price LA, Shen H, Chacko SA, Everlof G, Bostwick JS, Steinbacher TE, Li YX, Huang CS, Seiffert DA, Rehfuss R, Wexler RR, Lam PY.

ChemMedChem. 2014 Oct;9(10):2327-43. doi: 10.1002/cmdc.201402141. Epub 2014 Jul 2.


Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.

Yang W, Wang Y, Lai A, Qiao JX, Wang TC, Hua J, Price LA, Shen H, Chen XQ, Wong P, Crain E, Watson C, Huang CS, Seiffert DA, Rehfuss R, Wexler RR, Lam PY.

J Med Chem. 2014 Jul 24;57(14):6150-64. doi: 10.1021/jm5006226. Epub 2014 Jul 7.


Inhibition of Factor XI activity as a promising antithrombotic strategy.

Chen Z, Seiffert D, Hawes B.

Drug Discov Today. 2014 Sep;19(9):1435-9. doi: 10.1016/j.drudis.2014.04.018. Epub 2014 May 2. Review.


Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.

Jeon YT, Yang W, Qiao JX, Li L, Ruel R, Thibeault C, Hiebert S, Wang TC, Wang Y, Liu Y, Clark CG, Wong HS, Zhu J, Wu DR, Sun D, Chen BC, Mathur A, Chacko SA, Malley M, Chen XQ, Shen H, Huang CS, Schumacher WA, Bostwick JS, Stewart AB, Price LA, Hua J, Li D, Levesque PC, Seiffert DA, Rehfuss R, Wexler RR, Lam PY.

Bioorg Med Chem Lett. 2014 Mar 1;24(5):1294-8. doi: 10.1016/j.bmcl.2014.01.066. Epub 2014 Jan 31.


Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.

Quan ML, Wong PC, Wang C, Woerner F, Smallheer JM, Barbera FA, Bozarth JM, Brown RL, Harpel MR, Luettgen JM, Morin PE, Peterson T, Ramamurthy V, Rendina AR, Rossi KA, Watson CA, Wei A, Zhang G, Seiffert D, Wexler RR.

J Med Chem. 2014 Feb 13;57(3):955-69. doi: 10.1021/jm401670x. Epub 2014 Jan 17.


Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.

Xu Y, Cai TQ, Castriota G, Zhou Y, Hoos L, Jochnowitz N, Loewrigkeit C, Cook JA, Wickham A, Metzger JM, Ogletree ML, Seiffert DA, Chen Z.

Thromb Haemost. 2014 Apr 1;111(4):694-704. doi: 10.1160/TH13-08-0668. Epub 2013 Dec 12.


Does plexin-B1, a semaphorin 4D receptor, play a role in thrombosis?

Bird E, Smith PL, Seiffert D, Psaltis GC, Huang J, Schumacher WA.

Thromb Res. 2013 Jun;131(6):564-5. doi: 10.1016/j.thromres.2013.03.018. Epub 2013 Apr 30. No abstract available.


Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.

Wang TC, Qiao JX, Clark CG, Jua J, Price LA, Wu Q, Chang M, Zheng J, Huang CS, Everlof G, Schumacher WA, Wong PC, Seiffert DA, Stewart AB, Bostwick JS, Crain EJ, Watson CA, Rehfuss R, Wexler RR, Lam PY.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3239-43. doi: 10.1016/j.bmcl.2013.03.125. Epub 2013 Apr 6.


Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait.

Bird JE, Smith PL, Wang X, Schumacher WA, Barbera F, Revelli JP, Seiffert D.

Thromb Haemost. 2012 Jun;107(6):1141-50. doi: 10.1160/TH-11-10-0682. Epub 2012 Mar 8.


Challenges and promises of developing thrombin receptor antagonists.

Yang J, Xu K, Seiffert D.

Recent Pat Cardiovasc Drug Discov. 2010 Nov;5(3):162-70. Review.


Inhibition of factor XIa as a new approach to anticoagulation.

Schumacher WA, Luettgen JM, Quan ML, Seiffert DA.

Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):388-92. doi: 10.1161/ATVBAHA.109.197178. Epub 2010 Feb 5. Review.


The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression.

Burton CR, Meredith JE, Barten DM, Goldstein ME, Krause CM, Kieras CJ, Sisk L, Iben LG, Polson C, Thompson MW, Lin XA, Corsa J, Fiedler T, Pierdomenico M, Cao Y, Roach AH, Cantone JL, Ford MJ, Drexler DM, Olson RE, Yang MG, Bergstrom CP, McElhone KE, Bronson JJ, Macor JE, Blat Y, Grafstrom RH, Stern AM, Seiffert DA, Zaczek R, Albright CF, Toyn JH.

J Biol Chem. 2008 Aug 22;283(34):22992-3003. doi: 10.1074/jbc.M804175200. Epub 2008 Jun 23.


Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.

Bird JE, Giancarli MR, Allegretto N, Barbera F, Wong P, Schumacher WA, Ogletree ML, Seiffert D.

Thromb Res. 2008;123(1):146-58. doi: 10.1016/j.thromres.2008.03.010. Epub 2008 May 14.


A renaissance for the contact system in blood coagulation?

Blat Y, Seiffert D.

Thromb Haemost. 2008 Mar;99(3):457-60. doi: 10.1160/TH07-11-0692. No abstract available.


Supplemental Content

Loading ...
Support Center